Frederic Wohlwend to take over as CIO of Merck KGaA

Will replace Kai Beckman, who moves to global human resources

Frederic Wohlwend will take over as chief information officer (CIO) of Merck KGaA on 1 April, succeeding Kai Beckmann, who will join the Merck executive board with responsibility for global human resources on that date. Wohlwend will report directly to chairman Karl-Ludwig Kley.

Wohlwend has been senior vice president, information services for Merck’s Chemicals business, which includes the Performance Materials and Merck Millipore divisions.

Prior to this, he was senior vice president, information services for Merck’s Pharmaceuticals business, which includes the Merck Serono and Consumer Health Care divisions.

Wohlwend joined Merck in 2007 with the acquisition of the Swiss biotech pharmaceutical company Serono SA. He joined Serono in 1991 and held positions of increasing responsibility, latterly as CIO.

You may also like

Research & Development

Quibim partners with Merck KGaA to develop imaging-based diagnostics

Quibim and Merck KGaA have partnered to develop diagnostic tools which will fortify the implementation of personalised medicine
Sustainability

Altenex Energy advises Merck KGaA on power purchase agreement for 130 MW of new wind and solar in Spain

Deal advances Merck KGaA, Darmstadt, Germany’s climate commitments and will deliver needed renewable energy to the region
Manufacturing

MilliporeSigma invests $25m into cell culture media

The subsidiary of Merck has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space in the process
Manufacturing

Improving the operational efficiency of single-use assemblies in liquid bioprocessing

Merck recently announced the launch of its Ultimus Single-Use Process Container Film, which has been designed to provide extreme durability and leak resistance for the single-use assemblies used during bioprocessing liquid applications. Dr Kevin Robinson spoke to Greg Verni, Head of Single-Use and Systems, to find out more
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Drug Delivery

Merck invests €290m in biosafety testing capacity

The company aims to increase its Group sales to approximately €25 billion by 2025
Manufacturing

Merck opens commercial facility in France

The Martillac facility is designed to operate at the highest levels of efficiency and can rapidly pivot from 200 to 2000 litres of drug substance
Subscribe now